South Korea Greenlights ACRYL-D01: AI's New Ally in Depression Diagnosis
In a groundbreaking move, South Korea's Ministry of Food and Drug Safety has approved ACRYL-D01, marking the country's first AI-powered tool for supporting depression diagnosis. Developed by Acryl, this innovative software analyzes patient interviews to assess the likelihood of depression. The approval showcases South Korea's growing embrace of AI in healthcare, aiming to enhance early detection and treatment of mental health issues. With potential to streamline mental health diagnostics, ACRYL-D01 paves the way for further AI applications in the medical field.
Jan 3